WP1066, an AG49 derivative, is a novel and potent inhibitor of Janus kinases-JAK2 and STAT3 with potential antitumor activity.

Ropsacitinib (PF-06826647; Tyk2-IN-8; PF06826647) is a novel, selective and orally bioavailable TYK2 (tyrosine kinase) inhibitor with potential anti-inflammatory activity.

AT-9283 L-lactate is a novel, potent multikinase inhibitor with potential antineoplastic activity and has the potential for the treatment of multiple myeloma.

Gandotinib (formerly also known as LY2784544) is a novel, potent and selective JAK2 (Janus kinase) inhibitor with potential antitumor activity.

Fedratinib dihydrochloride hydrate (SAR302503 or TG101348) is a novel, potent, selective, orally bioavailable, small-molecule and ATP-competitive inhibitor of janus kinase 2 (JAK2) with the inhibition constant IC50 of 3 nM.

Peficitinib (formerly ASP015K and JNJ54781532) is a novel, potent and orally bioavailable inhibitor of Janus kinase-JAK with potential anti-inflammatory activities.

Protosappanin A is a novel and potent immunosuppressive agent isolated from Caesalpinia sappan L.

Go6976 (also known as PD-40697) is a novel, potent and selective inhibitor of PKC (Protein Kinase C)with potential antitumor activity.

NVP-BSK805 2HCl (BSK805), the dihydrochloride salt of NVP-BSK805, is a novel, potent, selective and ATP-competitive JAK2 (Janus kinase) inhibitor with potential antitumor activity.

Upadacitinib tartrate (formerly ABT494; ABT-494; rinvoq), the tartrate salt of Upadacitinib, is a novel, potent and selective Janus kinase (JAK) 1 inhibitor approved in 2019 for the treatment of rheumatoid arthritis.